Haleon stock gains on GLP-1 sales lift

Haleon stock (ISIN GB00BMX86B70) traded at USD 9.22 on September 17, 2026, and MarketBeat said HLN opened at USD 9.22 on the same day. The shares were also reported at GBP 339.90 in London trading, showing the dual listing setup that investors still watch closely.

GLP-1 demand

As CNBC reported on September 16, 2026, a Haleon spokesperson said the company's dual placement strategy in core aisles and GLP-1 destination sets delivered an average 24 percent sales lift per store. The same report said Haleon is targeting U.S. consumers using weight-loss drugs, which gives the stock a concrete operating hook rather than a pure valuation story.

As Seeking Alpha reported on September 16, 2026, Haleon has seen an uptick in U.S. sales of products such as Advil and Tums as GLP-1 users buy remedies for side effects. That matters because it ties a consumer trend to branded over-the-counter demand.

Organic growth stays modest

The Daily Upside said on September 17, 2026, that Haleon shares had fallen 9.3 percent in 2026 while organic revenue growth was 2.6 percent in the first six months of the year. That comparison is the key tension in the story: a stock that has lagged in 2026, but a business that is still producing mid-single-digit line growth in the latest half-year period.

GuruFocus said on September 16, 2026, that HLN was trading at USD 9.25 per share, about 8.3 percent below its intrinsic GF Value of USD 10.09. That adds a second dated market reference to the picture, although the operating case is still more important than a one-day valuation snapshot.

Price and positioning

Haleon stock was quoted at USD 9.22 on September 17, 2026, with MarketBeat also saying the shares opened at USD 9.22. In London, Sharecast reported HLN at 339.90 pence on September 17, 2026, which keeps the stock close to the same level across the two market views.

More news and analyses on Haleon stock